Trial | NCT01293552  Report issue

Title

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne
Clinical Trial To Evaluate Botulinum Neurotoxin Type A (ANT-1207) In Subjects With Acne

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    72
The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of acne.
Study Started
Jan 31
2011
Primary Completion
Apr 30
2012
Study Completion
Jul 31
2012
Last Update
Jul 04
2013
Estimate

Biological ANT-1207

single dose application

Biological Vehicle

  • Other names: Placebo

Control Placebo Comparator

blank vehicle formulation

Dose 1 Experimental

Dose 1

Dose 2 Experimental

Dose 2

Dose 3 Experimental

Dose 3

Dose 4 Experimental

Dose 4

Criteria 

Inclusion Criteria:

diagnosis of moderate to severe facial acne
15 to 40 papules and pustules, and 5 to 50 open and/or closed comedones
no presence of nodules
female subjects must be not pregnant and non-lactating

Exclusion Criteria:

presence of 1 or more nodules
use of topical steroids on the face 4 weeks prior and during the study
use of systemic corticosteroids 6 weeks prior and during the study
topical or systemic acne treatment in the 4 weeks prior to Baseline
No Results Posted